Thermo Fisher Scientific (TMO): financials, SEC filings and peers

Thermo Fisher Scientific (TMO) is a life sciences tools & services company in the Health Care sector of the S&P 500, headquartered in Waltham, Massachusetts.

It was founded in 2006 and joined the S&P 500 on August 3, 2004.

Its fiscal year ends in December, and its shares trade on the NYSE.

In its SEC filings it is classified as “Measuring & Controlling Devices, NEC”.

Thermo Fisher Scientific at a glance

Revenue (12 months): $47.4B
Revenue growth: +8.3%
Operating margin: 17.9%
Net income (12 months): $7.1B
Free cash flow (12 months): $7.6B
Cash: $5.5B
Debt: $41.1B
Diluted EPS (12 months): $18.96

Twelve months to September 26, 2026, from the 10-Q filed October 30, 2026.

Latest twelve months

Over the twelve months to September 26, 2026, Thermo Fisher Scientific reported revenue of $47.4 billion, up 8.3% from a year earlier.

Its operating margin was 17.9%: for every $100 of sales, about $18 was left as operating profit.

Net income was $7.1 billion (14.9% of revenue), 7.6% higher than a year earlier.

Operating cash flow was $9.3 billion and capital spending $1.7 billion, leaving free cash flow of $7.6 billion (16.0% of revenue).

At the end of the period it held $5.5 billion in cash and $41.1 billion in debt, a net debt position of $35.6 billion.

The diluted share count fell 1.9% in a year, typically the result of buybacks.

Five-year trend

Revenue went from $32.2 billion in fiscal 2020 to $44.6 billion in fiscal 2025, about 6.7% a year.
Operating margin narrowed from 24.2% to 17.4% over the same years.
Free cash flow was positive in each of the last 6 fiscal years.

Fiscal year	2021	2022	2023	2024	2025
Revenue	$39.2B	$44.9B	$42.9B	$42.9B	$44.6B
Revenue growth	21.7%	14.5%	-4.6%	0.1%	3.9%
Operating margin	25.6%	18.7%	16.0%	17.1%	17.4%
Net income	$7.7B	$7.0B	$6.0B	$6.3B	$6.7B
Free cash flow	$6.8B	$6.9B	$6.9B	$7.3B	$6.3B
Diluted EPS	$19.46	$17.63	$15.45	$16.53	$17.74

Fiscal years as reported in Thermo Fisher Scientific’s 10-K filings. Free cash flow is operating cash flow minus capital spending.

Recent SEC filings

8-K filed October 30, 2026 — Executive or director change
10-Q filed October 30, 2026 — quarterly report
8-K filed October 21, 2026 — Earnings results
10-Q filed July 31, 2026 — quarterly report
8-K filed July 23, 2026 — Earnings results
8-K filed May 26, 2026 — Shareholder vote results
10-Q filed May 1, 2026 — quarterly report
8-K filed April 23, 2026 — Earnings results

All Thermo Fisher Scientific filings on SEC EDGAR

Companies like Thermo Fisher Scientific

Other S&P 500 companies in Life Sciences Tools & Services:

More from Health Care

All 60 Health Care companies →

Questions about Thermo Fisher Scientific

Is Thermo Fisher Scientific's revenue growing?

Yes. Revenue for the twelve months to September 26, 2026 was $47.4 billion, up 8.3% from a year earlier, according to its SEC filings.

Is Thermo Fisher Scientific profitable?

Yes. It earned $7.1 billion in net income over the twelve months to September 26, 2026, a net margin of 14.9%.

Does Thermo Fisher Scientific have more cash or more debt?

At September 26, 2026 it had $5.5 billion in cash and $41.1 billion in debt, so more debt than cash.

When did Thermo Fisher Scientific last file financial results?

Its latest quarterly report (10-Q) was filed with the SEC on October 30, 2026.

Which companies are similar to Thermo Fisher Scientific?

In the S&P 500, Thermo Fisher Scientific is grouped in Life Sciences Tools & Services within the Health Care sector. Agilent Technologies (A), Charles River Laboratories (CRL), Danaher Corporation (DHR), Illumina, Inc. (ILMN), IQVIA (IQV) are in the same group.

Understand the numbers

Source: Thermo Fisher Scientific’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved November 11, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.